BlackRock’s TherapeuticsMD TXMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$254K Hold
115,145
﹤0.01% 4751
2026
Q1
$233K Sell
115,145
-987
-0.8% -$2.22K ﹤0.01% 4727
2025
Q4
$189K Hold
116,132
﹤0.01% 4739
2025
Q3
$125K Hold
116,132
﹤0.01% 4788
2025
Q2
$135K Hold
116,132
﹤0.01% 4768
2025
Q1
$107K Hold
116,132
﹤0.01% 4753
2024
Q4
$99.9K Hold
116,132
﹤0.01% 4793
2024
Q3
$193K Sell
116,132
-9,020
-7% -$15.7K ﹤0.01% 4533
2024
Q2
$201K Sell
125,152
-10,627
-8% -$21.5K ﹤0.01% 4546
2024
Q1
$311K Sell
135,779
-484
-0.4% -$1.12K ﹤0.01% 4493
2023
Q4
$307K Sell
136,263
-242
-0.2% -$584 ﹤0.01% 4539
2023
Q3
$412K Sell
136,505
-622
-0.5% -$2.35K ﹤0.01% 4480
2023
Q2
$565K Buy
137,127
+20,995
+18% +$82.4K ﹤0.01% 4451
2023
Q1
$435K Hold
116,132
﹤0.01% 4561
2022
Q4
$649K Buy
116,132
+115,386
+15,467% +$679K ﹤0.01% 4539
2022
Q3
$5K Sell
746
-121,392
-99% -$983K ﹤0.01% 5636
2022
Q2
$1.22M Sell
122,138
-366,712
-75% -$3.5M ﹤0.01% 4459
2022
Q1
$9.29M Sell
488,850
-9,046
-2% -$142K ﹤0.01% 3617
2021
Q4
$8.85M Sell
497,896
-8,235
-2% -$247K ﹤0.01% 3750
2021
Q3
$18.8M Buy
506,131
+9,332
+2% +$414K ﹤0.01% 3317
2021
Q2
$29.6M Sell
496,799
-55,149
-10% -$3.34M ﹤0.01% 3065
2021
Q1
$37M Buy
551,948
+123,563
+29% +$9.67M ﹤0.01% 2822
2020
Q4
$25.9M Buy
428,385
+54,552
+15% +$3.72M ﹤0.01% 2878
2020
Q3
$29.5M Sell
373,833
-51,448
-12% -$4.1M ﹤0.01% 2634
2020
Q2
$26.6M Buy
425,281
+66,519
+19% +$3.87M ﹤0.01% 2652
2020
Q1
$19M Sell
358,762
-6,421
-2% -$637K ﹤0.01% 2632
2019
Q4
$44.2M Buy
365,183
+34,809
+11% +$5M ﹤0.01% 2448
2019
Q3
$60M Buy
330,374
+10,551
+3% +$1.49M ﹤0.01% 2184
2019
Q2
$41.6M Buy
319,823
+11,532
+4% +$2.07M ﹤0.01% 2431
2019
Q1
$75.1M Sell
308,291
-25,460
-8% -$6.74M ﹤0.01% 2054
2018
Q4
$63.6M Buy
333,751
+12,340
+4% +$3.01M ﹤0.01% 2094
2018
Q3
$105M Buy
321,411
+30,741
+11% +$9.42M ﹤0.01% 1936
2018
Q2
$90.7M Buy
290,670
+12,169
+4% +$3.72M ﹤0.01% 2010
2018
Q1
$67.8M Sell
278,501
-10,136
-4% -$2.84M ﹤0.01% 2080
2017
Q4
$87.2M Buy
288,637
+66,149
+30% +$18.4M ﹤0.01% 1956
2017
Q3
$58.9M Sell
222,488
-3,367
-1% -$973K ﹤0.01% 2189
2017
Q2
$59.5M Buy
225,855
+5,699
+3% +$1.43M ﹤0.01% 2133
2017
Q1
$79.3M Buy
220,156
+219,769
+56,788% +$68M ﹤0.01% 1924
2016
Q4
$111K Buy
387
+61
+19% +$18.9K ﹤0.01% 2481
2016
Q3
$111K Buy
326
+22
+7% +$8.04K ﹤0.01% 2525
2016
Q2
$129K Buy
304
+67
+28% +$27.6K ﹤0.01% 2377
2016
Q1
$76K Buy
237
+130
+121% +$44.3K ﹤0.01% 2132
2015
Q4
$56K Buy
107
+14
+15% +$5.17K ﹤0.01% 1991
2015
Q3
$27K Buy
93
+44
+90% +$15.6K ﹤0.01% 2213
2015
Q2
$19K Sell
49
-5
-9% -$1.76K ﹤0.01% 2434
2015
Q1
$16K Buy
54
+5
+10% +$1.22K ﹤0.01% 2471
2014
Q4
$11K Hold
49
﹤0.01% 2721
2014
Q3
$11K Hold
49
﹤0.01% 2681
2014
Q2
$11K Buy
49
+7
+17% +$1.56K ﹤0.01% 2728
2014
Q1
$13K Hold
42
﹤0.01% 2577
2013
Q4
$11K Hold
42
﹤0.01% 2668
2013
Q3
$6K Hold
42
﹤0.01% 2937
2013
Q2
$6K Buy
+42
New +$5.75K ﹤0.01% 2968

Other funds holding TXMD

BlackRock's TXMD Position: Q2 2026 in Review

BlackRock held its TherapeuticsMD (TXMD) position steady in Q2 2026 at 115,145 shares worth $254K. The position accounts for ﹤0.01% of the portfolio, ranked #4751.

BlackRock first reported a position in TXMD in Q2 2013 and has held it in 53 quarters since. The position peaked at $105M in Q3 2018. 45 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

  • BlackRock held 115,145 shares of TherapeuticsMD worth $254K as of Q2 2026.
  • BlackRock left its TherapeuticsMD share count unchanged in Q2 2026.
  • TherapeuticsMD made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4751 holding.
  • BlackRock first reported a position in TherapeuticsMD in Q2 2013 and has held it in 53 quarters since.
  • BlackRock's TherapeuticsMD position peaked at $105M in Q3 2018.
  • 45 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.